{"id":3271,"date":"2026-04-10T08:29:21","date_gmt":"2026-04-10T05:29:21","guid":{"rendered":"https:\/\/merkezlaboratuvari.com\/test-listesi\/insulin-90-dk-2\/"},"modified":"2026-04-21T12:38:42","modified_gmt":"2026-04-21T09:38:42","slug":"insulin-90-dk","status":"publish","type":"page","link":"https:\/\/merkezlaboratuvari.com\/ar\/test-listesi\/insulin-90-dk\/","title":{"rendered":"\u0130ns\u00fclin, 90. dk."},"content":{"rendered":"<h1>\u0130ns\u00fclin, 90. dk.<\/h1>\n<h2>Laboratuvar Bilgileri<\/h2>\n<ul>\n<li><strong>Yeni Kod:<\/strong> BIO5629<\/li>\n<li><strong>SUT Kodu:<\/strong> L103790<\/li>\n<li><strong>Eski Kod:<\/strong> HR0161<\/li>\n<li><strong>Kategori:<\/strong> Biyokimya<\/li>\n<li><strong>Numune T\u00fcr\u00fc:<\/strong> Serum<\/li>\n<li><strong>Numune Kab\u0131:<\/strong> Sar\u0131 Kapak<\/li>\n<li><strong>\u00c7al\u0131\u015fma G\u00fcn\u00fc:<\/strong> Her g\u00fcn<\/li>\n<li><strong>\u00d6nemli Kriter:<\/strong> \u00c7al\u0131\u015fma g\u00fcn\u00fcnde laboratuvar\u0131m\u0131zda kabul edilen testler, bir sonraki \u00e7al\u0131\u015fma program\u0131nda i\u015fleme al\u0131nacakt\u0131r.<\/li>\n<li><strong>Raporlama Tarihi:<\/strong> Ayn\u0131 g\u00fcn 18:00<\/li>\n<\/ul>\n<h2>\u0130ns\u00fclin, 90. dk. Testi Nedir?<\/h2>\n<p>\u0130ns\u00fclin, 90. dk., laboratuvar ortam\u0131nda de\u011ferlendirilen bir biyokimya testidir. De\u011ferlendirme \u00e7o\u011fu zaman serum \u00f6rne\u011fi \u00fczerinden planlan\u0131r.<\/p>\n<ul>\n<li><strong>Tam Adi:<\/strong> \u0130ns\u00fclin (A\u00e7lik \u0130ns\u00fclini \/ Serum \u0130ns\u00fclin D\u00fczeyi)<\/li>\n<li><strong>Kisaltmasi:<\/strong> IRI (\u0130mm\u00fcnoreaktif \u0130ns\u00fclin)<\/li>\n<li><strong>Neyi \u00d6l\u00e7er:<\/strong> Pankreastaki Langerhans adaciklarinin beta h\u00fccrelerinden salgilanan ins\u00fclin hormonunun kandaki d\u00fczeyini \u00f6l\u00e7er. \u0130ns\u00fclin, kan sekerinin h\u00fccrelere alinmasini saglayan ana hormondur ve glukoz metabolizmasinin temel d\u00fczenleyicisidir.<\/li>\n<\/ul>\n<p>Bu testin klinik anlam\u0131; istem nedeni, hastan\u0131n yak\u0131nmalar\u0131, ya\u015f\u0131, e\u015flik eden hastal\u0131klar\u0131, kullan\u0131lan y\u00f6ntem ve di\u011fer laboratuvar bulgular\u0131 ile birlikte de\u011ferlendirilir. Bu nedenle sonu\u00e7, tek ba\u015f\u0131na de\u011fil, b\u00fct\u00fcnc\u00fcl t\u0131bbi \u00e7er\u00e7eve i\u00e7inde yorumlanmal\u0131d\u0131r.<\/p>\n<h2>\u0130ns\u00fclin, 90. dk. Hangi Durumlarda \u0130stenir?<\/h2>\n<p>\u0130ns\u00fclin, 90. dk. testi, hekim taraf\u0131ndan klinik gereklilik g\u00f6r\u00fclen durumlarda istenebilir. \u0130stem gerek\u00e7esi hastan\u0131n mevcut tablosuna g\u00f6re de\u011fi\u015febilir.<\/p>\n<ul>\n<li>\u0130ns\u00fclin direnci (ins\u00fclin rezistansi) degerlendirmesi<\/li>\n<li>Tip 2 diyabet riski ve metabolik sendrom taramasi<\/li>\n<li>Hipoglisemi arastirmasi (ins\u00fclinoma s\u00fcphesi)<\/li>\n<li>PKOS degerlendirmesinde ins\u00fclin direnci saptanmasi<\/li>\n<li>HOMA-IR hesaplanmasi (a\u00e7lik glukoz ve ins\u00fclin ile)<\/li>\n<li>Tip 1 ve Tip 2 diyabet ayirici tanisi<\/li>\n<li>Obezite ve metabolik degerlendirme<\/li>\n<li>Faktisiy\u00f6z hipoglisemi s\u00fcphesi (eksojen ins\u00fclin kullanimi)<\/li>\n<\/ul>\n<p>Ayn\u0131 test farkl\u0131 hastalarda farkl\u0131 klinik sorulara yan\u0131t aramak amac\u0131yla kullan\u0131labildi\u011fi i\u00e7in, nihai de\u011ferlendirme her zaman ki\u015fisel t\u0131bbi \u00f6yk\u00fc ve muayene bulgular\u0131 ile birlikte yap\u0131lmal\u0131d\u0131r.<\/p>\n<h2>\u0130ns\u00fclin, 90. dk. Testi \u00d6ncesi Haz\u0131rl\u0131k<\/h2>\n<p>Haz\u0131rl\u0131k gereksinimi; testin t\u00fcr\u00fcne, numune yap\u0131s\u0131na ve laboratuvar\u0131n \u00e7al\u0131\u015fma kurallar\u0131na g\u00f6re de\u011fi\u015febilir. Test \u00f6ncesinde laboratuvar\u0131n ve hekimin verdi\u011fi talimatlar esas al\u0131nmal\u0131d\u0131r.<\/p>\n<ul>\n<li><strong>En az 8\u201312 saat a\u00e7lik<\/strong> gereklidir.<\/li>\n<li>Sabah erken saatlerde numune alinmalidir.<\/li>\n<li>\u0130ns\u00fclin enjeksiyonu yapan hastalar bunu hekimlerine bildirmelidir.<\/li>\n<li>Stres ve egzersizden ka\u00e7inilmalidir.<\/li>\n<\/ul>\n<p>Kullan\u0131lan ila\u00e7lar, takviyeler, yak\u0131n d\u00f6nemde ge\u00e7irilen hastal\u0131klar ve e\u015flik eden kronik durumlar sonucun yorumlanmas\u0131n\u0131 etkileyebilece\u011fi i\u00e7in sa\u011fl\u0131k profesyoneli ile payla\u015f\u0131lmal\u0131d\u0131r.<\/p>\n<h2>\u0130ns\u00fclin, 90. dk. Testi Nas\u0131l Yap\u0131l\u0131r?<\/h2>\n<p>\u0130ns\u00fclin, 90. dk. testi, uygun biyolojik \u00f6rnek al\u0131nd\u0131ktan sonra laboratuvar\u0131n belirledi\u011fi y\u00f6ntemle \u00e7al\u0131\u015f\u0131l\u0131r. Numunenin do\u011fru zamanda, uygun kapta ve uygun ta\u015f\u0131ma ko\u015fullar\u0131nda ula\u015ft\u0131r\u0131lmas\u0131 test kalitesi a\u00e7\u0131s\u0131ndan \u00f6nem ta\u015f\u0131r.<\/p>\n<ul>\n<li><strong>Numune T\u00fcr\u00fc:<\/strong> Serum<\/li>\n<li><strong>Numune Kab\u0131:<\/strong> Sar\u0131 Kapak<\/li>\n<li><strong>\u00c7al\u0131\u015fma G\u00fcn\u00fc:<\/strong> Her g\u00fcn<\/li>\n<li><strong>\u00d6nemli Kriter:<\/strong> \u00c7al\u0131\u015fma g\u00fcn\u00fcnde laboratuvar\u0131m\u0131zda kabul edilen testler, bir sonraki \u00e7al\u0131\u015fma program\u0131nda i\u015fleme al\u0131nacakt\u0131r.<\/li>\n<li><strong>Raporlama Tarihi:<\/strong> Ayn\u0131 g\u00fcn 18:00<\/li>\n<\/ul>\n<ul>\n<li><strong>Numune Tipi:<\/strong> Ven\u00f6z kan (serum)<\/li>\n<li><strong>Numune Alimi:<\/strong> Koldan standart kan alma islemiyle yaklasik 5 mL kan alinir.<\/li>\n<li><strong>Y\u00f6ntem:<\/strong> Imm\u00fcnoassay (kemil\u00fcminesans)<\/li>\n<li><strong>Sonu\u00e7 S\u00fcresi:<\/strong> 1 is g\u00fcn\u00fc<\/li>\n<\/ul>\n<p>Baz\u0131 durumlarda \u00f6rnek kalitesi, numune miktar\u0131, ta\u015f\u0131ma s\u00fcresi veya teknik tekrar gereksinimi raporlama s\u00fcresini ve sonucun g\u00fcvenilirli\u011fini etkileyebilir.<\/p>\n<h2>\u0130ns\u00fclin, 90. dk. Testi Ka\u00e7 G\u00fcnde \u00c7\u0131kar?<\/h2>\n<p>Mevcut laboratuvar bilgisine g\u00f6re bu test i\u00e7in raporlama s\u00fcresi: <strong>Ayn\u0131 g\u00fcn 18:00<\/strong> \u015feklindedir.<\/p>\n<p>Numunenin kabul zaman\u0131, laboratuvar\u0131n \u00e7al\u0131\u015fma plan\u0131, resmi tatiller veya gerekti\u011finde tekrar \u00e7al\u0131\u015fma gibi etkenler sonucu etkileyebilece\u011fi i\u00e7in en g\u00fcncel bilgi rapor tarihi \u00fczerinden de\u011ferlendirilmelidir.<\/p>\n<h2>Referans De\u011ferleri ve Sonu\u00e7lar\u0131n De\u011ferlendirilmesi<\/h2>\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Durum<\/th><th>Deger Araligi<\/th><\/tr><\/thead><tbody><tr><td>A\u00e7lik ins\u00fclini (yetiskin)<\/td><td>2,6 \u2013 24,9 \u00b5IU\/mL<\/td><\/tr><tr><td>\u0130ns\u00fclin direnci s\u00fcphesi<\/td><td>> 25 \u00b5IU\/mL<\/td><\/tr><\/tbody><\/table><\/figure>\n\n<h3>HOMA-IR (Homeostasis Model Assessment of Insulin Resistance)<\/h3>\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Form\u00fcl<\/th><th>HOMA-IR = (A\u00e7lik glukoz [mg\/dL] x A\u00e7lik ins\u00fclin [\u00b5IU\/mL]) \/ 405<\/th><\/tr><\/thead><tbody><tr><td>Normal<\/td><td>< 2,5<\/td><\/tr><tr><td>\u0130ns\u00fclin direnci<\/td><td>> 2,5<\/td><\/tr><tr><td>Belirgin ins\u00fclin direnci<\/td><td>> 4,0<\/td><\/tr><\/tbody><\/table><\/figure>\n\n<p>> *Not: Referans degerleri laboratuvarlar ve populasyonlara g\u00f6re degisebilir.*<\/p>\n<p>Referans bilgileri; kullan\u0131lan y\u00f6ntem, ya\u015f grubu, biyolojik \u00f6rnek tipi ve laboratuvar standard\u0131na g\u00f6re de\u011fi\u015febilece\u011finden, rapor \u00fczerinde yer alan laboratuvar yorumu esas al\u0131nmal\u0131d\u0131r.<\/p>\n<h2>\u0130ns\u00fclin, 90. dk. Sonucu Nas\u0131l Yorumlan\u0131r?<\/h2>\n<p>Test sonucu tek ba\u015f\u0131na kesin tan\u0131 koydurmaz. Sonu\u00e7; klinik bulgular, di\u011fer laboratuvar verileri ve gerekli g\u00f6r\u00fcld\u00fc\u011f\u00fcnde ek incelemeler ile birlikte de\u011ferlendirilir.<\/p>\n<h3>\u0130ns\u00fclin Y\u00fcksekligi (Hiperinsulinemi)<\/h3>\n<ul>\n<li><strong>\u0130ns\u00fclin direnci<\/strong> (Tip 2 diyabetin erken evresi, metabolik sendrom, obezite)<\/li>\n<li><strong>\u0130ns\u00fclinoma<\/strong> (pankreas beta h\u00fccre t\u00fcm\u00f6r\u00fc \u2014 hipoglisemiyle birlikte y\u00fcksek ins\u00fclin)<\/li>\n<li>PKOS<\/li>\n<li>Cushing sendromu<\/li>\n<li>Akromegali<\/li>\n<li>Eksojen ins\u00fclin kullanimi (faktisiy\u00f6z hipoglisemi)<\/li>\n<\/ul>\n<h3>\u0130ns\u00fclin D\u00fcs\u00fckl\u00fcg\u00fc<\/h3>\n<ul>\n<li><strong>Tip 1 diyabet<\/strong> (otoimm\u00fcn beta h\u00fccre yikimi)<\/li>\n<li>\u0130leri Tip 2 diyabet (beta h\u00fccre t\u00fckenmesi)<\/li>\n<li>Pankreatektomi sonrasi<\/li>\n<li>Pankreas hastaliklari (kronik pankreatit)<\/li>\n<li>Hipopit\u00fcitarizm<\/li>\n<\/ul>\n<h3>Hipoglisemi Ayirici Tanisi<\/h3>\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>\u0130ns\u00fclin<\/th><th>C-Peptit<\/th><th>Yorum<\/th><\/tr><\/thead><tbody><tr><td>Y\u00fcksek<\/td><td>Y\u00fcksek<\/td><td>\u0130ns\u00fclinoma veya s\u00fclfonil\u00fcre kullanimi<\/td><\/tr><tr><td>Y\u00fcksek<\/td><td>D\u00fcs\u00fck<\/td><td>Eksojen ins\u00fclin (faktisiy\u00f6z hipoglisemi)<\/td><\/tr><tr><td>D\u00fcs\u00fck<\/td><td>D\u00fcs\u00fck<\/td><td>Non-ins\u00fclinomat\u00f6z hipoglisemi<\/td><\/tr><\/tbody><\/table><\/figure>\n\n<p>\u00d6zellikle s\u0131n\u0131rda, d\u00fc\u015f\u00fck d\u00fczeyli veya beklenmeyen sonu\u00e7larda klinik korelasyon gerekir. Gerekti\u011finde tekrar test, panel de\u011ferlendirmesi veya ek laboratuvar incelemeleri planlanabilir.<\/p>\n<h2>Testin S\u0131n\u0131rl\u0131l\u0131klar\u0131<\/h2>\n<p>Her laboratuvar testinde oldu\u011fu gibi bu incelemenin de baz\u0131 s\u0131n\u0131rl\u0131l\u0131klar\u0131 vard\u0131r. Sonu\u00e7; \u00f6rnek kalitesi, \u00f6rnekleme zaman\u0131, ta\u015f\u0131ma ko\u015fullar\u0131 ve klinik ba\u011flamdan etkilenebilir.<\/p>\n<ul>\n<li>Tek bir laboratuvar sonucu, klinik \u00e7er\u00e7eve d\u0131\u015f\u0131nda eksik yorumlanabilir.<\/li>\n<li>Uygun olmayan numune kalitesi sonucun g\u00fcvenilirli\u011fini azaltabilir.<\/li>\n<li>Gerekti\u011finde ek testler olmadan tek ba\u015f\u0131na karar vermek yan\u0131lt\u0131c\u0131 olabilir.<\/li>\n<\/ul>\n<h2>Olas\u0131 Riskler<\/h2>\n<p>Risk \u00e7o\u011funlukla numune alma ve numune y\u00f6netimi s\u00fcreci ile ili\u015fkilidir. Testin kendisinden \u00e7ok, \u00f6rne\u011fin al\u0131nmas\u0131 ve uygun ko\u015fullarda \u00e7al\u0131\u015f\u0131lmas\u0131 \u00f6nem ta\u015f\u0131r.<\/p>\n<ul>\n<li>Kan alma islemi g\u00fcvenlidir; hafif agri, morarma olabilir.<\/li>\n<li>A\u00e7lik kosullarinda numune alinmasi esastir; tokluk durumunda ins\u00fclin fizyolojik olarak y\u00fckselir.<\/li>\n<li>\u0130ns\u00fclin direnci degerlendirmesinde <strong>a\u00e7lik glukozu ile birlikte<\/strong> HOMA-IR hesaplanmasi daha anlamlidir.<\/li>\n<li>Eksojen ins\u00fclin kullanan hastalar da (Tip 1 veya Tip 2) bunu mutlaka bildirmelidir; bazi immunoassayler eksojen ins\u00fclini de \u00f6l\u00e7er.<\/li>\n<li>Hipoglisemi arastirmasinda ins\u00fclin, <strong>C-peptit ve proins\u00fclin<\/strong> ile birlikte degerlendirilmelidir.<\/li>\n<li>Hemolizli numunelerde ins\u00fclin parcalanabilir; uygun numune kosullari saglanmalidir.<\/li>\n<li>\u0130ns\u00fclin antikorlari varliginda (ins\u00fclin tedavisi alan hastalarda) immunoassay sonu\u00e7lari yaniltici olabilir.<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u0130ns\u00fclin, 90. dk. Laboratuvar Bilgileri Yeni Kod: BIO5629 SUT Kodu: L103790 Eski Kod: HR0161 Kategori: Biyokimya Numune T\u00fcr\u00fc: Serum Numune Kab\u0131: Sar\u0131 Kapak \u00c7al\u0131\u015fma G\u00fcn\u00fc: Her g\u00fcn \u00d6nemli Kriter: \u00c7al\u0131\u015fma g\u00fcn\u00fcnde laboratuvar\u0131m\u0131zda kabul edilen testler, bir sonraki \u00e7al\u0131\u015fma program\u0131nda i\u015fleme al\u0131nacakt\u0131r. Raporlama Tarihi: Ayn\u0131 g\u00fcn 18:00 \u0130ns\u00fclin, 90. dk. Testi Nedir? \u0130ns\u00fclin, 90. dk., laboratuvar [&hellip;]<\/p>\n","protected":false},"author":0,"featured_media":0,"parent":5,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"test_category":"Biyokimya","test_kodu":"BIO5629","numune_turu":"Serum","numune_kabi":"Sar\u0131 Kapak","calisma_gunu":"Her g\u00fcn","onemli_kriter":"\u00c7al\u0131\u015fma g\u00fcn\u00fcnde laboratuvar\u0131m\u0131zda kabul edilen testler, bir sonraki \u00e7al\u0131\u015fma program\u0131nda i\u015fleme al\u0131nacakt\u0131r.","raporlama_tarihi":"Ayn\u0131 g\u00fcn 18:00","numune_red_kriterleri":"","aktarim_kodu":"","loinc_kodu":"","sut_kodu":"L103790","akredite":"","numune_miktari":"","alternatif_ornek":"","numune_alinma_sekli":"","stabilite_ozellikleri":"","calisma_yontemi":"","test_bilgisi":"","footnotes":""},"class_list":["post-3271","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/pages\/3271","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/types\/page"}],"replies":[{"embeddable":true,"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/comments?post=3271"}],"version-history":[{"count":4,"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/pages\/3271\/revisions"}],"predecessor-version":[{"id":8961,"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/pages\/3271\/revisions\/8961"}],"up":[{"embeddable":true,"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/pages\/5"}],"wp:attachment":[{"href":"https:\/\/merkezlaboratuvari.com\/ar\/wp-json\/wp\/v2\/media?parent=3271"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}